{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
INN:fandosentan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fandosentan (CI 1034 or PD 180988) is an endothelin A receptor antagonist. It inhibits pulmonary vasoconstriction. Fandosentan was being developed for the treatment of chronic obstructive pulmonary disease and pulmonary hypertension.
Status:
Investigational
Source:
NCT00479505: Phase 2 Interventional Completed Urinary Bladder, Overactive
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Gisadenafil is a phosphodiesterase V inhibitor in clinical development at Pfizer. It had been in phase II clinical trials for the treatment of Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladder. Treatment-emergent adverse events were: headache, myalgia, dyspepsia, back pain.
Status:
Investigational
Source:
NCT00048022: Phase 2 Interventional Completed Asthma
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Valategrast (R-411) is a dual-acting α4/β1 - α4/β7 integrin antagonist which underwent clinical development with Roche for the treatment of multiple sclerosis (MS) and asthma. Phase I and II studies have been
conducted. It had shown good efficacy in animal disease models. Following oral administration, R-411 was rapidly
and completely biotransformed into its active metabolite, RO-0270608, most of which was eliminated by biliary excretion. R-411 had shown acceptable pharmacokinetics and
good safety in healthy volunteers. R-411 inhibited eosinophil and T H 2 cell excitation and survival, and inhibited eosinophil migration from blood to pulmonary tissues. The idea of combining R-411 with montelukast (leukotriene antagonist) in the pharmaceutical dosage
forms, therefore, provided a therapeutic treatment that had the combined effect of reducing circulating eosinophil counts
and reducing eosinophil egress into pulmonary tissues, thereby providing an early onset of bronchodilation as well as sustained anti-inflammatory effects. Valategrast had been in phase II clinical trials by Roche for the treatment of asthma and in phase I clinical trials for the treatment of multiple sclerosis (MS). However, the study had been discontinued. Development of Valategrast was
discontinued for the treatment of asthma after clarification of the regulatory framework for that class of compounds.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Razinodil was developed as a coronary vasodilator, a drug that reduces blood pressure by dilating blood vessels. It was tested for its potential as a drug in ischemic myocardial diseases. In a canine heart-lung laboratory model, it increased coronary blood flow without increasing oxygen consumption. Only slight negative chronotropic (heart rate) and inotropic (cardiac contraction) effects were reported. Razinodil also improved the survival rate of miniature pigs after an induced heart attack.
Status:
Investigational
Source:
NCT00832546: Phase 1 Interventional Completed Healthy
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Tezampanel, also known as LY 293558 and NGX-424, is a drug originally developed by Eli Lilly, which is a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family. Tezampanel was in phase II clinical trial for treatment migraine, but this study was discontinued. Also this drug has several others potential pharmacological actions, one of them is anxiety disorders
Class (Stereo):
CHEMICAL (RACEMIC)
Cliropamine (D 16427) is a positive inotropic compound.
Status:
Investigational
Source:
Acta Trop. Apr 1997;65(1):23-31.: Not Applicable Veterinary clinical trial Completed Trypanosomiasis, African/blood/prevention & control
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ethidium is a DNA intercalating agent first discovered as and used as a veterenary trypanocide. A bromide salt is commonly used as a fluorescent tag in molecular biology. The fluorescene of ethidium bromide increased 21 fold upon binding to double-stranded RNA, 25 fold upon binding double stranded DNA. Because of the binding to DNA, ethidium bromide is a powerful inhibitor of DNA polymerase.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Etipirium is an antihaemorrhagic and spasmolytic drug.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
FLUDAZONIUM is a topical antiinfective agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Mefexamide is a psychostimulant. It was studied in the treatment of depression, asthenia and parkinsonism.
